Maneesh Arora
Madison-based Elephas Biosciences Corp. announced Tuesday the completion of a $40 million series B-2 funding round.
Elephas is developing an oncology diagnostics platform that can predict response to immunotherapy.
The platform uses live fragments from a patient biopsy and treats those fragments with potential therapies and combinations. The latest advances in cancer biology combined with multi-modal imaging are used to assess how patients will respond before beginning treatment.
The capital raised will support the launch and commercialization of the Elephas Live Platform as a laboratory developed test in 2026.
“This financing milestone underscores the strong investor confidence in the promise of Elephas and our shared mission to improve the lives of those affected by cancer,” said Maneesh Arora, founder and CEO of Elephas. “We have made incredible progress this year and have strong momentum heading into 2026. This funding achievement will drive our next stage of growth and advance our commercialization strategy.”
In 2022, the company completed a $41.5 million Series B funding round. This was followed by a $55 million series C funding round in 2024.
-
Elizabeth Morin is a writer based in Virginia Beach. She is passionate about local sports, politics and everything in between.
Have any Virginia Beach-related news published on our website? Email us at admin at thevirginiabeachobserver.com.
View all posts
Related
